<DOC>
	<DOCNO>NCT00416494</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine , oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some find tumor cell kill carry tumor-killing substance . Others interfere ability tumor cell grow spread . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving capecitabine oxaliplatin together bevacizumab may kill tumor cell . PURPOSE : This phase II trial study well give oxaliplatin capecitabine together bevacizumab work treat patient metastatic recurrent colorectal cancer .</brief_summary>
	<brief_title>Capecitabine , Oxaliplatin , Bevacizumab Treating Patients With Metastatic Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate response rate patient previously untreated metastatic colorectal cancer treat capecitabine , oxaliplatin , bevacizumab . Secondary - Assess time progression ( TTP ) , disease-free survival ( DFS ) , overall survival ( OS ) patient treat regimen . - Assess safety tolerability bevacizumab , oxaliplatin , capecitabine patient previously untreated metastatic colorectal cancer . Exploratory - Evaluate effect regimen biomarkers angiogenesis . - Assess effect regimen wound angiogenesis . OUTLINE : Patients receive oral capecitabine twice daily day 1-5 8-12 , oxaliplatin IV 2 hour day 1 , bevacizumab IV 1-1½ hour day 1 . Courses repeat every 14 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document adenocarcinoma colon rectum Metastatic recurrent disease amenable potentially curative treatment ( e.g. , inoperable metastatic disease ) No leptomeningeal brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 AST/ALT &lt; 2.5 time upper limit normal ( ULN ) ( 5 time ULN know liver metastasis ) Bilirubin &lt; 1.5 time ULN Creatinine clearance &gt; 50 mL/min No unstable poorly control hypertension ( &gt; 150/100 mm Hg ) Patients recently start adjust antihypertensive medication eligible provide blood pressure &lt; 140/90 mm Hg new regimen least 3 different observation 14 day Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study least 34 month study completion No arterial venous thrombosis ( include cerebrovascular accident ) within last 3 month No know , exist , uncontrolled coagulopathy No clinically significant cardiac disease No congestive heart failure No symptomatic coronary artery disease No cardiac arrhythmias well control medication No myocardial infarction within last 12 month No history allergic reaction attribute compound similar chemical biologic composition oxaliplatin , capecitabine , bevacizumab No history disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication PRIOR CONCURRENT THERAPY : At least 4 week since prior sorivudine brivudine At least 6 month since prior adjuvant treatment fluorouracil leucovorin calcium fluorouracil leucovorin calciumbased regimen No major surgery within 4 week without complete recovery No prior chemotherapy metastatic/recurrent disease No cancer immunotherapy biologic therapy therapy No radiotherapy study No hormonal therapy cancer study No fulldose warfarin ( INR &gt; 1.5 ) , heparin ( &gt; 10,000 units/day ) , thrombolytic agent Allopurinol cimetidine discontinue prior start regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>